Abstract:Objective To develop an LC-MS/MS method for simultaneous determine the concentration of atorvastatin (AT) and its two active metabolites,ortho-hydmxyatorvastatin (o-AT) andpara-hydroxyatorvastatin (p-AT) in human plasma.Methods Deuterium-labeled compounds,o-AT-d5 and p-AT-d5were used as the internal standards.The analytes were extracted from human plasma through liquid liquid extraction method by using tert-butyl ether,after adding 5％ formic acid.The chromatographic separation was achieved on a CAPCELL PAK C18(2.0 mm× 100 mm,TYPE∶MG Ⅱ,5 μm) column with the mobile phase,consisted of a mixture of acetonitrile-5 mmol · L-1 ammonium acetate buffer-formic acid (46∶ 54∶ 0.143,v/v/v),in isocratic mode at a flow rate of 0.40 mL · min-1.Data acquisition was carried out in multiple reaction monitoring (MRM) mode.Analytes were detected on a tandem mass spectrometer,equipped with an electrospray ionization source that was operated in the positive mode,using the transitions of m/z 559.3→m/z 440.2 for atorvastatin,and m/z 575.3→m/z 440.2 for both ortho-and para-hydroxyatorvastatin.The selectivity,standard curve,precision and accuracy,extraction recoveries,matrix effect,carry over and stability were investigated.Results The linear range of atorvastatin was 0.05-100 ng · mL-1.The linear regression equation was y =4.35 × 10-2x + 3.43 × 10-4 (r =0.999 3) with the lower limit of quantitation (LLOQ) of 0.05 ng · mL-1.The linear range of ortho-atorvastatin was 0.05-50 ng· mL-1.The linear regression equation was y =1.03 × 10-1x + 6.93 × 10-4 (r =0.998 7) with the lower limit of quantitation (LLOQ) of 0.05 ng · mL-1.The linear range of para-atorvastatin was 0.05-5.0 ng · mL-1.The linear regression equation was y =5.35 × 10-1 x-2.26 × 10-3 (r =0.998 4) with the lower limit of quantitation (LLOQ) of 0.05 ng · mL-1.The intra-day and inter-day relative standard deviations (RSD) of LLOQ,low,medium1,medium2 and high concentrations of atorvastatin were both less than 15％.The extraction recoveries were 61.64％-90.29％.The matrix effects were 88.74％-105.62％.Conclusion The established method is rapid,sensitive,accurate,specific and reliable,and suitablefor simultaneous determination of atorvastatin and its active metabolites (ortho-atorvastatin and para-atorvastatin) in human plasma,which meets the needs of clinical therapeutic drug monitoring and pharmacokinetics research.

Validated Ultra HPLC Method for the Simultaneous Determination of Atorvastatin, Aspirin, and their Degradation Products in Capsules

oncepts in development of fast, simple, stability indicating HPLC method for analysis of atorvastatin related compounds in tablets

Development and Validation of Ultra-Performance Liquid Chromatography (UPLC) Method for Simultaneous Quantification of Hydrochlorothiazide, Amlodipine Besylate, and Valsartan in Marketed Fixed-Dose Combination Tablet

Simultaneous Determination of Aspirin,Ethenzamide,Caffeine in AEC Tablet by HPLC

Development and validation of a stability-indicating, single HPLC method for sacubitril-valsartan and their stereoisomers and identification of forced degradation products using LC-MS/MS

HPLC–MS–MS for the Simultaneous Determination of Atorvastatin and Amlodipine in Plasma of Hypertensive Patients

Isolation, Characterization of a Potential Degradation Product of Aspirin and an HPLC Method for Quantitative Estimation of Its Impurities

Simultaneous determination of atorvastatin and its active metabolites in human plasma by LC-MS/MS

Development and Validation of RP-UPLC Method for the Determination of Process and Degradant Impurities Present in Dabigatran Etexilate Mesylate Capsules Using High Strength Silica-T3 Sorbent Column

THE USE OF A MONOLITHIC COLUMN TO IMPROVE THE SIMULTANEOUS DETERMINATION OF CAFFEINE, PARACETAMOL, PSEUDOEPHEDRINE, ASPIRIN, DEXTROMETHORPHAN, CHLORPHENIRAMINE IN PHARMACEUTICAL FORMULATIONS BY HPLC–A COMPARISON WITH A CONVENTIONAL REVERSED-PHASE SILICA-BASED COLUMN

Experimental Design Approach in HPLC Method Development: Application for the Simultaneous Determination of Sacubitril and Valsartan in Presence of Their Impurities and Investigation of Degradation Kinetics

COST EFFECTIVE STABILITY INDICATING RAPID, EFFICIENT ANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF RELATED SUBSTANCES METHOD FOR SIMULTANEOUS DETERMINATION OF SIMVASTATIN AND EZETIMIBE IN TABLET FORMULATIONS

Unveiling Impurities: A Comprehensive RP-HPLC Method for Accurate Atorvastatin Impurity Analysis in Pharmaceuticals Using Accuracy Profile Approach

A rapid method for the simultaneous determination of L-ascorbic acid and acetylsalicylic acid in aspirin C effervescent tablet by ultra performance liquid chromatography-tandem mass spectrometry

Development and Validation of Chromatographic Methods for Simultaneous Estimation of Aspirin and Pantoprazole Sodium in Pure and Mixture Form

A Robust and Reliable UPLC Method for the Simultaneous Quantification of Rosuvastatin Calcium, Glibenclamide, and Candesartan Cilexetil

A Novel Validated UHPLC Method for the Estimation of Rosuvastatin and Its Complete Impurity Profile in Tablet Formulations

A Stability Indicating RP-HPLC Method Validation for Simultaneous Estimation of Metformin HCl, Dapagliflozin and Saxagliptin in Pharmaceutical Dosage Form

A Supercritical Fluid Chromatography and Tandem Mass Spectrometry Method for the Simultaneous Quantification of Valsartan and Hydrochlorothiazide in Human Plasma

Management of validation of HPLC method for determination of acetylsalicylic acid impurities in a new pharmaceutical product

Stability‐indicating RP‐HPLC method development and validation for the quantification of amlodipine besylate and valsartan tablets in solid oral dosage form